AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Firefly Neuroscience, Inc.
Video analysis: AIFF
All videosNo video analysis for this stock yet. Request one from our team.
News: AIFF
Firefly Neuroscience (NASDAQ:AIFF) vs. Pro Medicus (OTCMKTS:PMCUF) Head-To-Head Analysis
Pro Medicus (OTCMKTS:PMCUF - Get Free Report) and Firefly Neuroscience (NASDAQ: AIFF - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, valuation and earnings. Insider and Institutional Ownership 5.0% of Firefly Neuroscience
Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes
KENMORE, N.Y., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence ("AI") company advancing precision neuroscience, today announced a close to four-fold (291%) year-over-year increase in Transcranial Magnetic Stimulation (“TMS”) center customer clinical assessments using its U.S. Food and Drug Administration (“FDA”) 510(k)-cleared, AI-powered EEG/ERP platform, Evoke™.
Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee's Recommendation Backs Broader Access to Key Neuroprotective Peptides
– FDA Advisory Committee voted to recommend easing compounding restrictions for six peptides, including Epitalon and Semax, late last week –
